Disease · MONDO_0018076

tuberculosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. tuberculosis. Diseases, record MONDO_0018076. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018076

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: tuberculosis; Open Targets
Open Targets ID: MONDO_0018076; Open Targets
Other names: Disease, Koch's, Disease, Kochs, Infection due to Mycobacterium tuberculosis, Infection due to Mycobacterium tuberculosis (disorder), Koch Disease, Koch's Disease, Kochs Disease, MTB - Mycobacterium tuberculosis infection, Mycobacterium tuberculosis infection, TB, TB - Tuberculosis, TB OF ORGAN NEC-CULT DX, TB OF ORGAN NEC-HISTO DX, TB OF ORGAN NEC-MICRO DX, TB OF ORGAN NEC-NO EXAM, TB OF ORGAN NEC-OTH TEST, TB OF ORGAN NEC-UNSPEC, TB ORGAN NEC-EXAM UNKN, Tuberculoma (finding), Tuberculoses, Tuberculosis (disorder), Tuberculosis NOS, Tuberculosis NOS (disorder), Tuberculosis of mother, with delivery, Tuberculosis of other organs, Tuberculosis of other organs (disorder), Tuberculosis of other organs NOS, Tuberculosis of other organs NOS (disorder), Tuberculosis of other specified organs, Tuberculosis of other specified organs (disorder), Tuberculosis of other specified organs NOS, Tuberculosis of other specified organs NOS (disorder), Tuberculosis of other specified organs, bacteriological or histological examination not done, Tuberculosis of other specified organs, bacteriological or histological examination unknown (at present), Tuberculosis of other specified organs, tubercle bacilli found (in sputum) by microscopy, Tuberculosis of other specified organs, tubercle bacilli not found (in sputum) by microscopy, but found by bacterial culture, Tuberculosis of other specified organs, tubercle bacilli not found by bacteriological examination, but tuberculosis confirmed histologically, Tuberculosis of other specified organs, tubercle bacilli not found by bacteriological or histological examination, but tuberculosis confirmed by other methods [inoculation of animals], Tuberculosis of other specified organs, unspecified examination, Tuberculosis pregnancy, Tuberculosis, antepartum, Tuberculosis, postpartum, Tuberculous, Tuberculous (qualifier value), [X]Tuberculosis of other specified organs, [X]Tuberculosis of other specified organs (disorder), tuberculoma, tuberculosis disease, tuberculous abscess; Open Targets
Disease Ontology: DOID:399; Disease Ontology
MeSH: D014376; MeSH
NCI Thesaurus: C3423; NCI Thesaurus
Orphanet: ORPHA:3389; Orphanet
Highest stage of its drugs: Approval, for 27 of its 134 drugs, from ATC, ClinicalTrials.gov, DailyMed, FDA, PMDA and TTD; Open Targets

Drugs134

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ISONIAZID	CHEMBL64	Small molecule	Approval	ATC, DailyMed and TTD	112	63	63	Drugs and targets
RIFAMPIN	CHEMBL374478	Small molecule	Approval	ATC, DailyMed, FDA and TTD	93	61	61	Drugs and targets
PYRAZINAMIDE	CHEMBL614	Small molecule	Approval	ATC and DailyMed	47	42	42	Drugs and targets
BEDAQUILINE	CHEMBL376488	Small molecule	Approval	ATC and ClinicalTrials.gov	33	32	32	Drugs and targets
ETHAMBUTOL	CHEMBL44884	Small molecule	Approval	ATC	33	32	32	Drugs and targets
DELAMANID	CHEMBL218650	Small molecule	Approval	ATC	19	18	18	Drugs and targets
PRETOMANID	CHEMBL227875	Small molecule	Approval	ATC, DailyMed and TTD	20	17	17	Drugs and targets
RIFAPENTINE	CHEMBL1660	Small molecule	Approval	ATC, DailyMed and TTD	20	17	17	Drugs and targets
RIFABUTIN	CHEMBL444633	Small molecule	Approval	ATC, PMDA and TTD	16	13	13	Drugs and targets
CYCLOSERINE	CHEMBL771	Small molecule	Approval	ATC and TTD	5	3	3	Drugs and targets

1 to 10 of 134

See all 134 drugs

Targets83

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGS2	Cyclooxygenase	4	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Phase 2	https://conductscience.org/library/genes/5743	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
OPRM1	Mu-type opioid receptor	3	Mu opioid receptor agonist; Opioid receptors; mu/kappa/delta antagonist	Phase 1	https://conductscience.org/library/genes/4988	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	2	HMG-CoA reductase inhibitor	Phase 2/3	https://conductscience.org/library/genes/3156	Drugs and targets
OPRK1	Kappa-type opioid receptor	2	Kappa opioid receptor agonist; Opioid receptors; mu/kappa/delta antagonist	Phase 1	https://conductscience.org/library/genes/4986	Drugs and targets
PTGS1	Cyclooxygenase	2	Cyclooxygenase inhibitor	Phase 2	https://conductscience.org/library/genes/5742	Drugs and targets
VDR	Vitamin D3 receptor	2	Vitamin D receptor agonist	Phase 3	https://conductscience.org/library/genes/7421	Drugs and targets
ABL1	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/613	Drugs and targets
CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	1	Neuronal acetylcholine receptor; alpha4/beta2 agonist	Phase 3	https://conductscience.org/library/genes/1137	Drugs and targets

1 to 10 of 83

See all 83 targets

Trials206

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01582711	Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT	Phase 3	1,002	2025-03-13	Latent Tuberculosis Infection	ISONIAZID, RIFAPENTINE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02821832	Using Biomarkers to Predict TB Treatment Duration	Phase 2	946	2022-12-20	Pulmonary Tuberculosis	ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN	Its record names the disease	ClinicalTrials.gov
NCT00255840	Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities	Not applicable	812	2011-06-16	HIV Infections	EFAVIRENZ, LAMIVUDINE, LOPINAVIR, NEVIRAPINE, RITONAVIR, STAVUDINE	Its record names the disease	ClinicalTrials.gov
NCT02259127	ODYSSEY (PENTA 20)	Phase 2/3	792	2025-07-29	HIV Infection	DOLUTEGRAVIR	Its record names the disease	ClinicalTrials.gov
NCT02153528	Optimization of the TB Treatment Regimen Cascade	Phase 3	701	2020-02-13	Tuberculosis, Pulmonary	RIFAMPIN	Its record names the disease	ClinicalTrials.gov
NCT02409290	The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB	Phase 3	588	2023-09-28	MDR-TB	BEDAQUILINE, CLOFAZIMINE, ETHAMBUTOL, ISONIAZID, KANAMYCIN, LEVOFLOXACIN, MOXIFLOXACIN, PROTIONAMIDE, PYRAZINAMIDE	Its record names the disease	ClinicalTrials.gov
NCT00685360	A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)	Phase 2	481	2021-12-01	Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis	DELAMANID	Its record names the disease	ClinicalTrials.gov
NCT01785186	Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design	Phase 2	365	2017-09-20	Tuberculosis, Pulmonary	ISONIAZID, MOXIFLOXACIN, RIFAMPIN, SQ109	Its record names the disease	ClinicalTrials.gov
NCT03089983	Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings	Not applicable	316	2026-02-09	Opioid Dependence, Addiction, HIV/AIDS, Tuberculosis, Hepatitis	ISONIAZID, METHADONE, RIFAPENTINE	Its record names the disease	ClinicalTrials.gov
NCT01936831	High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)	Phase 2	282	2023-02-17	Tuberculosis	ISONIAZID	Its record names the disease	ClinicalTrials.gov

1 to 10 of 206

See all 206 trials

Comparisons in its trials37

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Antiretroviral Therapy Monitored by Medical Officer vs Antiretroviral Therapy Managed by Primary Health Care Nurse: serious adverse events	126 of 408	153 of 404	812	NCT00255840	Trial comparisons
Standard TB Treatment vs Double Rimfampicin: deaths from any cause	17 of 348	12 of 353	701	NCT02153528	Trial comparisons
Standard TB Treatment vs Double Rimfampicin: serious adverse events	24 of 348	13 of 353	701	NCT02153528	Trial comparisons
Standard TB Treatment vs Double Rimfampicin: Number of Participants Who Develop Liver Toxicity	7 of 343	3 of 350	693	NCT02153528	Trial comparisons
3HP Self Administered Therapy (SAT) vs 3HP SAT With SMS Reminders: Treatment Completion Rates Between Participants Randomized to SAT Without Reminders Versus SAT With Weekly SMS Reminders	248 of 335	250 of 326	661	NCT01582711	Trial comparisons
Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weeks: Discontinuation Due to Experiencing an Adverse Event	10 of 156	1 of 156	312	NCT03089983	Trial comparisons
Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weks: deaths from any cause	0 of 156	0 of 156	312	NCT03089983	Trial comparisons
Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weks: serious adverse events	0 of 156	0 of 156	312	NCT03089983	Trial comparisons
Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weeks: TB Treatment Adherence	9 of 152	117 of 153	305	NCT03089983	Trial comparisons
Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weeks: TB Treatment Completion Rates in Prison	114 of 152	127 of 153	305	NCT03089983	Trial comparisons

1 to 10 of 37

See all 37 comparisons in its trials

Papers from its trials200

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40645198	RESULT	1	PubMed
39756697	RESULT	1	PubMed
39189858	RESULT	1	PubMed
38850838	RESULT	1	PubMed
38768617	RESULT	1	PubMed
38019456	RESULT	1	PubMed
37980911	RESULT	1	PubMed
37567554	RESULT	1	PubMed
36808186	RESULT	4	PubMed
36546625	RESULT	1	PubMed

1 to 10 of 200

See all 200 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018076

GET https://conductscience.org/api/diseases/v1/MONDO_0018076/drugs?page=2

API reference For AI assistants